ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic, Lung LB"
Episode Synopsis
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed
a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through
the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership.
He also provides advice to similar diagnostic companies seeking reimbursement and
compliance with the US FDA Lab Developed Test ruling.
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed
a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through
the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership.
He also provides advice to similar diagnostic companies seeking reimbursement and
compliance with the US FDA Lab Developed Test ruling.
More episodes of the podcast Citeline Podcasts
Datamonitor Healthcare Podcast: ESMO 2025
12/11/2025
Scrip's Five Must-Know Things - Nov. 4, 2025
04/11/2025
Drug Fix: US FDA Streamlines Biosimilar Development Requirements, Clarifies Inspection Reform
31/10/2025
In God we trust